18:34:23 EST Thu 19 Nov 2026
Enter Symbol
or Name
USA
CA



Microbix Biosystems Inc
Symbol MBX
Shares Issued 136,136,656
Close 2026-11-18 C$ 0.275
Market Cap C$ 37,437,580
Recent Sedar+ Documents

Microbix begins sales of custom biological materials

2026-11-19 15:58 ET - News Release

Mr. Cameron Groome reports

MICROBIX BEGINS SALES OF NEW PRODUCT CATEGORY

Microbix Biosystems Inc. has commercialized custom biological materials for incorporation into the lab-based assays or point-of-care test-cartridges of in-vitro diagnostics manufacturers (test-makers or DxMs). Initial sales have been made to two DxMs, each of which is incorporating a Microbix biologic material into a new assay or assays.

These materials are supplied to DxMs for further manufacturing and later incorporation into the DxMs' own finished assays as sample processing controls (SPCs). SPCs, sometimes referred to as in-cartridge controls, are known non-target biologic material that is processed together with each patient sample; if the test's target is not detected and the SPC fails, the test is reported as invalid rather than negative. Once incorporated by a DxM, these custom-made Microbix biological materials help a finished molecular assay confirm that critical stages, such as nucleic-acid extraction, amplification and detection, are each functioning. At present, Microbix expects to generate recurring sales to these DxMs and that additional DxM clients will be secured for such products. Sales of this new category of product are targeted to become material as client assays are commercialized and as further client programs and clients are secured.

Microbix can now provide such materials for both DNA- and RNA-based molecular assays -- for the latter, also covering the critical reverse-transcription (RT) step. With both DNA- and RNA-oriented biologic materials for further manufacturing, Microbix complements its lines of QAPs external quality assessment products and QUANTDx reference materials. Each of these three product classes can incorporate customized nucleic-acid sequences designed to meet the precise targeting needs of DxMs.

Phil Casselli, Microbix's senior vice-president of sales and business development, commented: "Unlike external quality assessment samples that clinical laboratories use periodically or are included one per box with test cartridges, these SPC-oriented materials are built into each test unit by the DxM. Adding this new product class rounds out our portfolio of offerings and strengthens our customer success philosophy -- supporting quality across the entire diagnostic assay ecosystem, from development and manufacturing through to regular clinical lab or point-of-need usage."

Pavel Zhelev, Microbix's director of product management, provided further explanation: "Even the best test designs are vulnerable to failure, which can result from many different causes. Consequently, an SPC that confirms each test has run correctly is necessary to secure regulatory approvals and reimbursement, for best-practice usage, and for patient safety. The Microbix team is pleased to supply custom biologic materials for further manufacturing that become the SPCs in the assays of our valued customers."

Further information about Microbix custom biologic materials for further SPC manufacturing, native or recombinant antigens, QAPs external quality assessment samples, QUANTDx reference materials, and control elution or sample-collection reagents (CEB and DxTM) is available on the Microbix website, while purchase enquiries can be e-mailed to customer.service@microbix.com.

About Microbix Biosystems Inc.

Microbix is a Canadian life sciences company working to advance global health through biological products that support diagnostic testing, laboratory quality assurance and disease management. With over 100 employees and fiscal 2025 revenues of $18.6-million, Microbix helps diagnostics companies, clinical laboratories and health care providers deliver accurate and reliable test results to improve patient care.

Microbix is an enabling partner to the global diagnostics industry, by providing proprietary antigens used by approximately 100 diagnostics manufacturers, alongside its portfolio of QAPs quality assessment products and QUANTDx reference materials. Its products support assay development and validation, technician training, site on boarding, external quality assessment, and quality assurance across entire test workflows. Microbix products are available in more than 30 countries through international distribution partners. The company maintains ISO 9001 and ISO 13485 certifications, U.S. Food and Drug Administration (FDA), and Australian Therapeutic Goods Administration (TGA) registrations, Health Canada licences, and European Union In Vitro Diagnostic Regulation (IVDR) and CE-mark compliance.

Microbix also leverages its biological expertise to advance other proprietary products, including the thrombolytic drug Kinlytic urokinase and reagents (DxTM) for test-sample collection or processing. Headquartered in Mississauga, Ont., Canada, Microbix trades on the Toronto Stock Exchange and OTCQX, supporting the quality, reliability and effectiveness of health care.

We seek Safe Harbor.

© 2026 Canjex Publishing Ltd. All rights reserved.